Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 4
2018 1
2019 2
2020 1
2021 1
2024 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.
Chanias I, Stojkov K, Stehle GT, Daskalakis M, Simeunovic H, Njue LM, Schnegg-Kaufmann AS, Porret NA, Allam R, Rao TN, Benz R, Ruefer A, Schmidt A, Adler M, Rovo A, Balabanov S, Stuessi G, Bacher U, Bonadies N, On Behalf Of The Swiss Mds Study Group. Chanias I, et al. Among authors: ruefer a. Cancers (Basel). 2021 Jun 30;13(13):3296. doi: 10.3390/cancers13133296. Cancers (Basel). 2021. PMID: 34209457 Free PMC article. Review.
Iron metabolism in patients with Graves' hyperthyroidism.
Fischli S, von Wyl V, Trummler M, Konrad D, Wueest S, Ruefer A, Heering K, Streuli R, Steuer C, Bernasconi L, Recher M, Henzen C. Fischli S, et al. Among authors: ruefer a. Clin Endocrinol (Oxf). 2017 Nov;87(5):609-616. doi: 10.1111/cen.13450. Epub 2017 Sep 14. Clin Endocrinol (Oxf). 2017. PMID: 28833367 Free article.
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.
Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK). Drexler B, et al. Among authors: ruefer a. Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8. Haematologica. 2019. PMID: 30409796 Free PMC article. Clinical Trial.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C. Mey UJ, et al. Among authors: ruefer a. Br J Haematol. 2017 Mar;176(5):770-782. doi: 10.1111/bjh.14481. Epub 2016 Dec 16. Br J Haematol. 2017. PMID: 27983764 Clinical Trial.
11 results